Tegaserod in constipation associated with Parkinson disease

John Christopher Morgan, Kapil Dev Sethi

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalClinical Neuropharmacology
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2007

    Fingerprint

Keywords

  • 5-HT agonist
  • Constipation
  • Parkinson disease
  • Tegaserod

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this